Meeting
2014 ASCO Annual Meeting
Phase II trial of single agent PARP inhibitor ABT-888 (veliparib [vel]) followed by postprogression therapy of vel with carboplatin (carb) in patients (pts) with stage BRCA-associated metastatic breast cancer (MBC): California Cancer Consortium trial PHII-96.
Authors
George Somlo
City of Hope, Duarte, CA
George Somlo , Paul Henry Frankel , Thehang H. Luu , Cynthia Ma , Banu Arun , Agustin Garcia , Tessa Cigler , Leah Cream , Harold A. Harvey , Joseph A. Sparano , Rita Nanda , Helen K. Chew , Timothy Jerome Moynihan , Linda T. Vahdat , Matthew P. Goetz , Arti Hurria , Joanne E. Mortimer , David R. Gandara , Alice Chen , Jeffrey N. Weitzel
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Highlights Session
Session Title
Breast Cancer - Triple-Negative/Cytotoxics/Local Therapy
Track
Breast Cancer
Sub Track
Triple-Negative Breast Cancer
Clinical Trial Registration Number
NCT01149083
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 1021)
DOI
10.1200/jco.2014.32.15_suppl.1021
Abstract #
1021
Poster Bd #
14
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
![Efficacy of the PARP inhibitor (PI) ABT-888 (veliparib [vel]) either with carboplatin (carb) or as a single agent followed by post-progression therapy in combination with carb in patients (pts) with <i>BRCA1</i>- or <i>BRCA2</i>- (<i>BRCA</i>)-associated metastatic breast cancer (MBC).](https://d201v5jt9ylckg.cloudfront.net/156/10671/112102/112102_poster_pv.jpg)
Efficacy of the PARP inhibitor (PI) ABT-888 (veliparib [vel]) either with carboplatin (carb) or as a single agent followed by post-progression therapy in combination with carb in patients (pts) with BRCA1- or BRCA2- (BRCA)-associated metastatic breast cancer (MBC).
First Author: George Somlo
Poster
2024 ASCO Annual Meeting
PLATIPARP: A phase 2 study of induction docetaxel and carboplatin followed by maintenance rucaparib in treatment of patients with mCRPC with homologous recombination DNA repair deficiency.
First Author: Ruben Raychaudhuri
Poster
2018 ASCO Annual Meeting
An open-label, phase II study of rucaparib, a PARP inhibitor, in HER2- metastatic breast cancer patients with high genomic loss of heterozygosity.
First Author: Anne Patsouris
Poster
2018 Genitourinary Cancers Symposium
TRITON2: An international, multicenter, open-label, phase II study of the PARP inhibitor rucaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD).
First Author: Wassim Abida